On November 17, Teva Pharmaceutical fell 3.06% in Regular Trading, trading at $43.15 per share, with turnover of $168 million.
The latest catalyst was an FDA approval granted to Teva's US affiliate for at-home use of Igalmi sublingual film to treat agitation associated with mental disorders, expanding the product's use setting.
Teva had completed the BXCL501 asset acquisition in late October for $57.5 million upfront plus up to $67.5 million in contingent payments. The approval strengthens the company's CNS pipeline and follows a strong third quarter in which non-GAAP EPS reached $0.86 and combined revenue from AUSTEDO, AJOVY and UZEDY rose 33% year over year to about $1.1 billion, alongside raised full-year guidance. Despite the positive development, the share decline suggests investors were locking in gains after the recent rally tied to stronger innovation-drug momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments